Principal Financial Group
STOK icon

Principal Financial Group’s Stoke Therapeutics STOK Stock Holding History

Principal Financial Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Buy
69,880
+5,947
+9% +$191K ﹤0.01% 1824
2026
Q1 		$2.08M Sell
63,933
-6,349
-9% -$208K ﹤0.01% 1819
2025
Q4 		$2.23M Buy
70,282
+25,077
+55% +$754K ﹤0.01% 1822
2025
Q3 		$1.06M Buy
+45,205
New +$775K ﹤0.01% 1916
2024
Q2 		– Sell
-10,451
Closed -$141K – 2457
2024
Q1 		$141K Sell
10,451
-1,586
-13% -$9.61K ﹤0.01% 2233
2023
Q4 		$63.3K Sell
12,037
-94
-0.8% -$402 ﹤0.01% 2314
2023
Q3 		$47.8K Buy
12,131
+743
+7% +$4.89K ﹤0.01% 2349
2023
Q2 		$121K Buy
+11,388
New +$121K ﹤0.01% 2262
2021
Q3 		– Sell
-8,365
Closed -$282K – 2620
2021
Q2 		$282K Buy
+8,365
New +$296K ﹤0.01% 2381
2020
Q4 		– Sell
-6,658
Closed -$223K – 2458
2020
Q3 		$223K Buy
+6,658
New +$190K ﹤0.01% 2183

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Principal Financial Group's STOK Position: Q2 2026 in Review

Principal Financial Group increased its Stoke Therapeutics (STOK) stake by 9.3% in Q2 2026, buying an estimated $191K and bringing the position to 69,880 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1824.

Principal Financial Group first reported a position in STOK in Q3 2020 and has held it in 10 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Principal Financial Group held 69,880 shares of Stoke Therapeutics worth $2.29M as of Q2 2026.
  • Principal Financial Group bought 5,947 Stoke Therapeutics shares in Q2 2026, an estimated $191K.
  • Stoke Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1824 holding.
  • Principal Financial Group first reported a position in Stoke Therapeutics in Q3 2020 and has held it in 10 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.